Position in NVS
as of Jun 30, 2026
· filed Aug 13, 2026
Position Value
$577,356
+$144,616 QoQ
Shares Held
3,684
+30.0% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.06%
of 13F equity value
Holder Rank
#830
of 1,602 holders
Holding Since
Dec 2025
3 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in NVS Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026Prosperity Consulting Group, LLC holds $39,098,306 across 13 Drug Manufacturers - General names. NVS ranks #10 (1.5% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LLY |
ELI LILLY & Co
|
11,223 | $13,461,204 | |
| 2 | ABBV |
AbbVie Inc.
|
27,908 | $7,022,769 | |
| 3 | JNJ |
Johnson & Johnson
|
22,450 | $5,701,626 | |
| 4 | MRK |
Merck & Co., Inc.
|
27,182 | $3,492,887 | |
| 5 | GILD |
Gilead Sciences, Inc.
|
26,812 | $3,387,428 | |
| 6 | GSK |
GSK plc
|
31,262 | $1,638,754 | |
| 7 | PFE |
Pfizer Inc
|
44,889 | $1,080,927 | |
| 8 | AZN |
Astrazeneca PLC
|
4,762 | $902,970 |
All Filings in NVS
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $577,356 | 3,684 | Shares | Sole | 2026-08-13 | |
| 2026-03-31 | $432,740 | 2,833 | Shares | Sole | 2026-05-05 | |
| 2025-12-31 | $236,447 | 1,715 | Shares | Sole | 2026-02-17 | |
| No filing history on record for this holder in this stock. | ||||||